Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 60687-574; 55111-355; 62756-146; 62756-148; 62756-145; 75834-135; 51991-794; 33342-090; 49706-1826; 65862-650; 51991-795; 71209-012; 71209-015; 0904-6587; 62704-0122; 33342-092; 65862-651; 46708-066; 75834-134; 55111-354; 50379-0012; 33342-089; 46708-873; 71209-014; 65862-649; 65862-648; 62756-147; 0904-7107; 62756-136; 65372-1152; 55111-352; 55111-066; 71209-013; 55111-353; 65862-612; 75834-136; 72241-011; 33342-091; 53104-7571; 46708-064; 72241-013; 51991-796; 72241-012; 75834-133; 51991-793; 72241-014; 46708-065; 70518-3012; 46708-063
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Lacrimation disorder06.08.02.010--Not Available
Laryngitis22.07.03.001; 11.01.13.001--
Leukocytosis01.02.01.002--
Libido decreased19.08.03.001; 21.03.02.005--
Libido increased21.03.02.007; 19.08.03.002--
Lipase increased13.05.01.003--
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mastitis21.05.03.002; 11.01.02.001--
Melaena24.07.02.013; 07.12.02.004--Not Available
Meniere's disease17.02.12.003; 07.01.07.007; 04.04.02.003--Not Available
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Metrorrhagia21.01.01.006--Not Available
Micturition disorder20.02.02.005--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.010--Not Available
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 15 Pages